



Noxopharm 2024 AGM Chair's Address

Sydney, 19 November 2024: Innovative biotech company **Noxopharm Limited (ASX:NOX)** provides Noxopharm Non-Executive Chairman Mr Frederick Bart's address to the 2024 Annual General Meeting of Shareholders.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US registered, Australia based Nyrada Inc (ASX:NYR), a drug discovery and development company specialising in novel small molecule therapies.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Noxopharm 2024 AGM Chair's Address

Fellow Shareholders,

Thank you for taking the time to be here today, and I am pleased to welcome you to Noxopharm's 2024 Annual General Meeting.

As ever, we appreciate the ongoing support of all our shareholders, whether they have been with us for a long time or are relative newcomers to our business.

This year we are pleased to report substantial progress across the company, which has come about because of the strategic decisions we took some time ago.

As Chairman, I am particularly pleased about developments related to the Sofra technology platform.

One year ago at this meeting, I told you that the world of medicine was changing quickly due to advances in RNA technology, and we wanted Noxopharm to be part of that.

Over the past 12 months we have demonstrated that we do indeed have an important role to play.

We have continued developing our Sofra assets.

We have announced a clinical trial that will start next year.

And we have seen clear external interest in what we are doing, from companies around the world.

In fact, we have recently signed several Material Transfer Agreements with some large international companies, who are now studying our Sofra technology at their own expense, and that expense is for some of them not insignificant.

This gives us real encouragement, because it demonstrates to us that these companies understand the enormous potential of our Sofra platform and the potential value of our assets to them.

These developments should also reassure investors that we are on the right path, and that we are moving towards the ultimate goal of delivering commercial outcomes for our shareholders.

There is still much hard work to do, but the executive team and our highly trained staff are showing that they are turning this company around.

We are starting to be noticed, and we are building a portfolio of assets in both Sofra and Chroma that enable us to be optimistic for the future.

On behalf of the Board, I would like to thank all of our shareholders for their ongoing support, and offer a special thank you to those who participated in our recent fundraising.

We appreciate your confidence in the company, and we look forward to making substantial progress in the years ahead.

Thank you.